Maha Hussain, MD, of the University of Michigan, gives her expert perspective on changes in the treatment of hormone-naive disease.
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, summarizes a panel discussion on this important topic.
Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitive disease. To see the French language version of this video, click here.
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.
A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of metastatic disease, and what physicians need to know about the molecular genetics of testicular cancer.
